ArticleBMC infectious diseases2025

Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study.

Hiam Chemaitelly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.